{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:43:00Z","timestamp":1790044980406,"version":"4.0.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017346","name":"Nippon Boehringer Ingelheim Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12325-025-03215-6","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T04:52:35Z","timestamp":1747630355000},"page":"2988-3001","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Progressive Pulmonary Fibrosis: Current Status in Terminology and Future Directions"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-5459","authenticated-orcid":false,"given":"Yasuhiro","family":"Kondoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"12","key":"3215_CR1","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3390\/jcm7120476","volume":"7","author":"O Kalchiem-Dekel","year":"2018","unstructured":"Kalchiem-Dekel O, Galvin JR, Burke AP, Atamas SP, Todd NW. Interstitial lung disease and pulmonary fibrosis: a practical approach for general medicine physicians with focus on the medical history. J Clin Med. 2018;7(12):476.","journal-title":"J Clin Med"},{"key":"3215_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ddmod.2019.03.001","volume":"29\u201330","author":"TL Paget","year":"2019","unstructured":"Paget TL, Parkinson-Lawrence EJ, Orgeig S. Interstitial lung disease and surfactant dysfunction as a secondary manifestation of disease: insights from lysosomal storage disorders. Drug Discov Today Dis Model. 2019;29\u201330:35\u201342.","journal-title":"Drug Discov Today Dis Model"},{"issue":"6","key":"3215_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733\u201348.","journal-title":"Am J Respir Crit Care Med"},{"key":"3215_CR4","doi-asserted-by":"crossref","unstructured":"American Thoracic Society, European Respiratory Society. American Thoracic Society\/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002;165(2):277\u2013304.","DOI":"10.1164\/ajrccm.165.2.ats01"},{"issue":"1","key":"3215_CR5","doi-asserted-by":"publisher","first-page":"23988","DOI":"10.1038\/s41598-021-03481-8","volume":"11","author":"M Gagliardi","year":"2021","unstructured":"Gagliardi M, Berg DV, Heylen C-E, et al. Real-life prevalence of progressive fibrosing interstitial lung diseases. Sci Rep. 2021;11(1):23988.","journal-title":"Sci Rep"},{"issue":"2","key":"3215_CR6","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/all.15017","volume":"77","author":"H Barnes","year":"2022","unstructured":"Barnes H, Troy L, Lee CT, Sperling A, Strek M, Glaspole I. Hypersensitivity pneumonitis: current concepts in pathogenesis, diagnosis, and treatment. Allergy. 2022;77(2):442\u201353.","journal-title":"Allergy"},{"issue":"11","key":"3215_CR7","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","volume":"35","author":"M Wijsenbeek","year":"2019","unstructured":"Wijsenbeek M, Kreuter M, Olson A, et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019;35(11):2015\u201324.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"3215_CR8","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/09031936.00152106","volume":"29","author":"NI Chaudhary","year":"2007","unstructured":"Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007;29(5):976\u201385.","journal-title":"Eur Respir J"},{"issue":"1","key":"3215_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1165\/rcmb.2016-0217OC","volume":"57","author":"L Kn\u00fcppel","year":"2017","unstructured":"Kn\u00fcppel L, Ishikawa Y, Aichler M, et al. A novel antifibrotic mechanism of nintedanib and pirfenidone. Inhibition of collagen fibril assembly. Am J Respir Cell Mol Biol. 2017;57(1):77\u201390.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"18","key":"3215_CR10","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"issue":"5","key":"3215_CR11","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","volume":"9","author":"J Behr","year":"2021","unstructured":"Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase\u00a02b trial. Lancet Respir Med. 2021;9(5):476\u201386.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"3215_CR12","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3215_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12931-019-1022-1","volume":"20","author":"M Kolb","year":"2019","unstructured":"Kolb M, Va\u0161\u00e1kov\u00e1 M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20(1):57.","journal-title":"Respir Res"},{"issue":"1","key":"3215_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1164\/rccm.202201-0124OC","volume":"207","author":"JV Pugashetti","year":"2023","unstructured":"Pugashetti JV, Adegunsoye A, Wu Z, et al. Validation of proposed criteria for progressive pulmonary fibrosis. Am J Respir Crit Care Med. 2023;207(1):69\u201376.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"3215_CR15","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1164\/rccm.201105-0840OC","volume":"184","author":"RM du Bois","year":"2011","unstructured":"du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184(12):1382\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3215_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1164\/rccm.202205-0910LE","volume":"207","author":"YH Khor","year":"2023","unstructured":"Khor YH, Farooqi M, Hambly N, Kolb M, Ryerson CJ. Patient characteristics and survival for progressive pulmonary fibrosis using different definitions. Am J Respir Crit Care Med. 2023;207(1):102\u20135.","journal-title":"Am J Respir Crit Care Med"},{"key":"3215_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107656","volume":"227","author":"MG Macmurdo","year":"2024","unstructured":"Macmurdo MG, Ji X, Pimple P, Olson AL, et al. Proportion and predictors of FVC decline in patients with interstitial lung disease. Respir Med. 2024;227:107656.","journal-title":"Respir Med"},{"key":"3215_CR18","doi-asserted-by":"crossref","unstructured":"Vermant M, Goos T, Gogaert S, Carlon MS, Crem N, De Sadeleer L. Current definitions of progressive pulmonary fibrosis might be inaccurate: data from a cohort of patients with rheumatoid arthritis associated interstitial lung disease. Am J Respir Crit Care Med. 2023;207:A1498.","DOI":"10.1164\/ajrccm-conference.2023.207.1_MeetingAbstracts.A1498"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03215-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03215-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03215-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:14:30Z","timestamp":1750479270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03215-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3215"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03215-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"29 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors did not receive payment for development of this manuscript. Yasuhiro Kondoh reports advisory board fees from Asahi Kasei Pharma Corp, Boehringer Ingelheim, Chugai Pharmaceutical Co., Ltd., GSK, Healios K.K., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., LTD, Sanofi K.K., Shionogi Co, Ltd., Taiho Pharmaceutical Co., and lecture fees from Asahi Kasei Pharma Corp, Bristol Myers Squibb, Boehringer Ingelheim, Eisai Co, Ltd, Janssen Pharmaceutical K.K., KYORIN Pharmaceutical Co, Ltd, Mitsubishi Tanabe Pharma, NIPPON SHINYAKU CO., LTD, Novartis Pharma K.K., Shionogi Co, Ltd., Teijin Pharma Ltd. Yoshikazu Inoue reports grants from the Japanese Ministry of Health, Labour, and Welfare and the Japan Agency for Medical Research and Development; payment for presentations from Boehringer Ingelheim, Kyorin, Shionogi, GlaxoSmithKline, ThermoFisher; and has served as a consultant or steering committee member for Boehringer Ingelheim, Galapagos, Roche, Taiho, CSL Behring, Vicore Pharma, Savara.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}